Rapid Acceleration of Diagnostics (RADx®) Tech and ATP Programs
The RADx® Tech program is part of the NIH RADx® Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID.
The MakeMyTestCount.org website is an easy way to anonymously report test results for any brand of at-home COVID-19 test. This helps public health departments to assess needs and provide resources. Report your test results here.
COVID-19 Research across NIBIB
Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about this resource.
Videos
View videos about RADx® Tech/ATP programs, interviews with the NIBIB Director and more.
Program Contacts
RADx® Tech/ATP programmatic or technical inquiries: info.radx@poctrn.org
All other RADx® Tech/ATP Applicants: RADxNIBIB@mail.nih.gov
SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov
All others: COVID19NIBIB@nih.gov
Related Resources
Learn about clinical trials for treatments and vaccines at HHS Combat COVID
NIH COVID-19 Information for Applicants/Grantees
Media Inquiries: nibibpress@mail.nih.gov or 301-496-3500
About COVID-19
Research information from NIH | Español
Related News
NIH has announced winners of the RADx® Tech Fetal Monitoring Challenge, a $2 million prize competition to speed development of innovative medical technologies for fetal health diagnosis, detection and monitoring.
A team of engineers at the University of Houston has published a study in the journal Nature on how international air travel has influenced the spread of COVID-19 around the world. By using a newly developed AI tool, the team identified hotspots of infection linked to air traffic, pinpointing key areas that significantly contribute to disease transmission. Source: University of Houston Newsroom
NIBIB bioengineer Kaitlyn Sadtler has flourished as a leader of many impactful, interdisciplinary studies. For her role in shaping the future of medical research, TIME magazine has named Kaitlyn Sadtler to the TIME100 Next 2024 List.
NIBIB-funded researchers are working to bring in vivo gene editing to the fore. Through rational engineering of lipid nanoparticles, this collaborative team developed a way to effectively target specific organs in the body to precisely deliver therapeutic cargo, including gene-editing molecules. Their research demonstrated that a one-time treatment with their nanoparticles resulted in durable gene editing in mouse lungs for nearly two years. Further, their technique showed promise in correcting a mutation present in a currently untreatable form of cystic fibrosis in several models of the disease.
Due to its high accuracy, lab-based PCR testing is the gold standard for infectious disease diagnostics. Yet PCR's availability is limited, especially in low-resource settings. New research suggests a new kind of test could be more streamlined without sacrificing performance.